Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Siemens Healthineers Launches The World's First Photon-Counting CT Scanner

Executive Summary

Naeotom Alpha will allow for faster, more precise, and safer computed tomography imaging for cardiac imaging, oncology, and pulmonology.

You may also be interested in...



Varian And Antigen Effects Propel Siemens Healthineers To New Heights In FY21

Siemens Healthineers became only the fifth medtech to exceed $20bn annual revenues when it reported FY21 results, a performance that included exceptional elements and positive core IVD business developments.

News We’re Watching: Two Join Illumina Board, FDA Plans Health Equity Meeting, Pre-Eclampsia Test Cleared

This week, Illumina’s board added two independent members; the VA and the FDA agreed to collaborate on supply chain issues; and Think Surgical, Thermo Fisher Scientific and Blue Earth all landed FDA clearances.

Exec Chat: Abbott’s Burton Talks About Abbott’s Plans To Address Chronic Pain With SCS

Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s new labeling for Abbott’s spinal cord stimulation devices that includes non-surgical back pain.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel